Tokai Pharmaceuticals Obtains $23,000,000 Series D Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=05bcfc14-3ff6-4901-a30f-5e3b9d43f06c&Preview=1 - Date
9/20/2011 - Company Name
Tokai Pharmaceuticals - Mailing Address
One Broadway 11th floor Cambridge , MA 02142 - Company Description
The company develops biopharmaceutical products that focus on endocrine treatment. - Website
http://www.tokaipharmaceuticals.com - Transaction Type
Venture Equity - Transaction Amount
$23,000,000 - Transaction Round
Series D - Proceeds Purposes
The new money will go toward Tokai’s lone drug in development, galeterone (TOK-001), as it advances into the second of three phases of trials normally required for FDA approval. - M&A Terms
- Venture Investor
Novartis Venture Fund - Venture Investor
Apple Tree Partners - Venture Investor
Undisclosed
